• 260 patients enrolled in the SHIELD Phase 2 study, first headline results expected by the end of the year
• 2 additional Phase 1 studies have been launched in the USA and in France
• First IND for DAV132 cleared by the FDA
Paris (France), 3rd of July, 2019 – Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.
DAV132 is Da Volterra’s most advanced product, designed to preserve the intestinal microbiota of patients from antibiotic-induced disruption. It targets several clinical benefits such as prevention of Clostridioides difficile infection and increased clinical response to Immune Checkpoint Inhibitors (ICI) in patients receiving antibiotics and treated with ICI.
Full PR available here